Anti-Integrin αvβ6 Autoantibodies Predict Response and Treatment Persistence to Advanced Therapies in Ulcerative Colitis
Anti-αvβ6 autoantibodies predicted both treatment persistence and clinical remission after advanced therapies, highlighting their potential as a predictive biomarker in patients with active UC.
Authors
- 梅田 智子
- Satoshi Kuronuma (ORCID: https://orcid.org/0000-0003-1787-3994)
- T Hibi
- Shinji Okabayashi (ORCID: https://orcid.org/0000-0003-2683-9018)
- Kunio Asonuma (ORCID: https://orcid.org/0000-0001-9766-3553)
- Shunsuke Shibui (ORCID: https://orcid.org/0009-0006-2557-7043)
- Akira Nogami (ORCID: https://orcid.org/0009-0003-0706-0436)
- Galia Berman
- Shin Maeda
- Moeko Komatsu
- Kanade Serizawa
- S Sagami
- M Nakano
- Osamu Takeuchi
- Nitsan Maharshak
Institutions
- Tel Aviv University (IL)
- Kyoto University (JP)
- Tel Aviv Sourasky Medical Center (IL)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Clinical and Translational Gastroenterology
- Published
- 2026-02-03
- DOI
- https://doi.org/10.14309/ctg.0000000000000990
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00